License and supply agreement with Genuine Health
RNS & Investor News
New patent filing: Antimicrobial Resistant (AMR) Health Care Acquired Infections
19 May 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces a new patent filing. The filing protects advances made in OptiBiotix's skin division in identifying microbial proteins which have the potential to prevent Health Care Acquired Infections ("HCAI") caused by antimicrobial resistant ("AMR") superbugs such as MRSA. HCAIs lead to higher morbidity and mortality, and cost the NHS an estimated £1bn per year. This represents a global market opportunity of US$82bn.
The new patent filing reflects scientific advances in identifying microbial proteins which: -
i. Protect skin cells from being damaged by pathogenic bacteria reducing the likelihood of infection
ii. Prevents the growth of pathogens on the skin, reducing the risk of infection spread
iii. Displaces pathogens from colonised skin and prevents their reattachment. This reduces the risk of re-infection with resistant organisms
These proteins are likely to be delivered in creams or oils with the aim of reducing the risk of infection from AMR superbugs such as MRSA. The Company believes that this filing adds a further layer of protection to its growing intellectual property portfolio in skincare and opens up product opportunities in multi-billion dollar global markets including Skincare (US$121bn), HCAIs (US$82bn), Eczema (US$3.8bn), Psoriasis (US$7.4bn) and Wound care (US$18.3bn).
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the filing of this patent which protects the recent advances we have made in identifying microbial proteins which have the potential to prevent HCAIs caused by AMR superbugs. These proteins prevent skin damage, stop pathogenic bacteria from growing, and most importantly prevent it from reattaching, reducing the risk of reinfection with AMR superbugs. The mechanism of action is different from current treatments which may kill bacteria but then allow reattachment with more resistant bacteria. We see this as an exciting advance on current therapies and hope that it will make a significant contribution to diminish the pain and suffering cause by AMR to vulnerable patients in hospitals across the world."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP
|Tel: 020 7148 7900|
|Hybridan LLP (Joint Broker)
Claire Louise Noyce
|Tel: 020 3713 4581|
|Peterhouse Corporate Finance Ltd (Joint Broker)
Lucy Williams / Duncan Vasey
|Tel: 020 7469 0936|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020